H. R. 7148—132 
DEPARTMENTAL MANAGEMENT 
PROGRAM ADMINISTRATION 
For carrying out, to the extent not otherwise provided, the 
Department of Education Organization Act, including rental of con-
ference rooms in the District of Columbia and hire of three pas-
senger motor vehicles, $399,407,000: Provided, That, notwith-
standing any other provision of law, none of the funds provided 
by this Act or provided by previous Appropriations Acts to the 
Department of Education available for obligation or expenditure 
in the current fiscal year may be used for any activity relating 
to implementing a reorganization that decentralizes, reduces the 
staffing level, or alters the responsibilities, structure, authority, 
or functionality of the Budget Service of the Department of Edu-
cation, relative to the organization and operation of the Budget 
Service as in effect on January 1, 2018: Provided further, That 
none of the funds provided by this Act may be used to support 
a number of non-career employees that is more than the number 
of non-career employees as of December 31, 2022: Provided further, 
That the Department of Education shall support staffing levels 
necessary to fulfill its statutory responsibilities including carrying 
out programs, projects, and activities funded in this title of this 
Act in a timely manner. 
OFFICE FOR CIVIL RIGHTS 
For expenses necessary for the Office for Civil Rights, as author-
ized by section 203 of the Department of Education Organization 
Act, $140,000,000. 
OFFICE OF INSPECTOR GENERAL 
For expenses necessary for the Office of Inspector General, 
as authorized by section 212 of the Department of Education 
Organization Act, $67,500,000, of which $3,000,000 shall remain 
available through September 30, 2027. 
GENERAL PROVISIONS 
SEC. 301. No funds appropriated in this Act may be used 
to prevent the implementation of programs of voluntary prayer 
and meditation in the public schools. 
(TRANSFER OF FUNDS) 
SEC. 302. Not to exceed 1 percent of any discretionary funds 
(pursuant to the Balanced Budget and Emergency Deficit Control 
Act of 1985) which are appropriated for the Department of Edu-
cation in this Act may be transferred between appropriations, but 
no such appropriation shall be increased by more than 3 percent 
by any such transfer: Provided, That the transfer authority granted 
by this section shall not be used to create any new program or 
to fund any project or activity for which no funds are provided 
in this Act: Provided further, That the Committees on Appropria-
tions of the House of Representatives and the Senate are notified 
at least 15 days in advance of any transfer.
H. R. 7148—133 
SEC. 303. Funds appropriated in this Act and consolidated 
for evaluation purposes under section 8601(c) of the ESEA shall 
be available from July 1, 2026, through September 30, 2027. 
SEC. 304. (a) An institution of higher education that maintains 
an endowment fund supported with funds appropriated for title 
III or V of the HEA for fiscal year 2026 may use the income 
from that fund to award scholarships to students, subject to the 
limitation in section 331(c)(3)(B)(i) of the HEA. The use of such 
income for such purposes, prior to the enactment of this Act, shall 
be considered to have been an allowable use of that income, subject 
to that limitation. 
(b) Subsection (a) shall be in effect until titles III and V of 
the HEA are reauthorized. 
SEC. 305. Section 114(f) of the HEA (20 U.S.C. 1011c(f)) shall 
be applied by substituting ‘‘2026’’ for ‘‘2021’’. 
SEC. 306. Section 458(a)(4) of the HEA (20 U.S.C. 1087h(a)) 
shall be applied by substituting ‘‘2027’’ for ‘‘2021’’. 
SEC. 307. Funds appropriated in this Act under the heading 
‘‘Student Aid Administration’’ may be available for payments for 
student loan servicing to an institution of higher education that 
services outstanding Federal Perkins Loans under part E of title 
IV of the Higher Education Act of 1965 (20 U.S.C. 1087aa et 
seq.). 
SEC. 308. The Secretary may reserve not more than 0.5 percent 
from any amount made available in this Act for an HEA program, 
except for any amounts made available for subpart 1 of part A 
of title IV of the HEA, to carry out rigorous and independent 
evaluations and to collect and analyze outcome data for any program 
authorized by the HEA: Provided, That no funds made available 
in this Act for the ‘‘Student Aid Administration’’ account shall 
be subject to the reservation under this section: Provided further, 
That any funds reserved under this section shall be available 
through September 30, 2028: Provided further, That if, under any 
other provision of law, funds are authorized to be reserved or 
used for evaluation activities with respect to a program or project, 
the Secretary may also reserve funds for such program or project 
for the purposes described in this section so long as the total 
reservation of funds for such program or project does not exceed 
any statutory limits on such reservations: Provided further, That 
not later than 30 days prior to the initial obligation of funds 
reserved under this section, the Secretary shall submit to the 
Committees on Appropriations of the Senate and the House of 
Representatives, the Committee on Health, Education, Labor and 
Pensions of the Senate, and the Committee on Education and 
Workforce of the House of Representatives a plan that identifies 
the source and amount of funds reserved under this section, the 
impact on program grantees if funds are withheld for the purposes 
of this section, and the activities to be carried out with such funds. 
(INCLUDING TRANSFER OF FUNDS) 
SEC. 309. Of the amounts appropriated in this Act for ‘‘Institute 
of Education Sciences’’ from amounts available for Program 
Administration, up to $20,000,000 shall be available for the Sec-
retary of Education (‘‘the Secretary’’) to provide support services 
to the Institute of Education Sciences (including, but not limited 
to information technology services, lease or procurement of office
H. R. 7148—134 
space, human resource services, financial management services, 
financial systems support, budget formulation and execution, legal 
counsel, equal employment opportunity services, physical security, 
facilities management, acquisition and contract management, 
grants administration and policy, and enterprise risk management): 
Provided, That the Secretary shall calculate the actual amounts 
obligated and expended for such support services by using a 
standard Department of Education methodology for allocating the 
cost of all such support services: Provided further, That the Sec-
retary may transfer any amounts available for IES support services 
in excess of actual amounts needed for IES support services, as 
so calculated, to the ‘‘Program Administration’’ account from the 
‘‘Institute of Education Sciences’’ account: Provided further, That 
in order to address any shortfall between amounts available for 
IES support services and amounts needed for IES support services, 
as so calculated, the Secretary may transfer necessary amounts 
to the ‘‘Institute of Education Sciences’’ account from the ‘‘Program 
Administration’’ account: Provided further, That the Committees 
on Appropriations of the House of Representatives and the Senate 
are notified at least 14 days in advance of any transfer made 
pursuant to this section. 
(RESCISSION AND TRANSFER OF FUNDS) 
SEC. 310. Of the unobligated balances in the ‘‘Department 
of Education Nonrecurring Expenses Fund’’ established in section 
313 of division H of Public Law 116–260, $160,000,000 are hereby 
rescinded not later than September 30, 2026: Provided, That from 
any remaining unobligated balances in such Fund, the Secretary 
may transfer up to $60,000,000 to ‘‘Innovation and Improvement’’ 
to be merged with funds made available under such heading for 
carrying out activities authorized under part C of title IV of the 
ESEA. 
(RESCISSION) 
SEC. 311. Of the funds made available under the heading 
‘‘Institute of Education Sciences’’ pursuant to section 1101(a)(8) 
of the Full-Year Continuing Appropriations Act, 2025 (division A 
of Public Law 119–4) for program administration, $25,000,000 are 
hereby permanently rescinded not later than September 30, 2026. 
SEC. 312. The Secretary shall award to each State an amount 
as required under the applicable provisions of the ESEA, McKinney- 
Vento Homeless Assistance Act, IDEA, Perkins Act, and AEFLA 
for each formula grant program to which funds are appropriated 
in this Act on the date such funds become available for obligation. 
This title may be cited as the ‘‘Department of Education Appro-
priations Act, 2026’’.
H. R. 7148—135 
TITLE IV 
RELATED AGENCIES 
COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR 
SEVERELY DISABLED 
SALARIES AND EXPENSES 
For expenses necessary for the Committee for Purchase From 
People Who Are Blind or Severely Disabled (referred to in this 
title as ‘‘the Committee’’) established under section 8502 of title 
41, United States Code, $13,124,000: Provided, That in order to 
authorize any central nonprofit agency designated pursuant to sec-
tion 8503(c) of title 41, United States Code, to perform requirements 
of the Committee as prescribed under section 51–3.2 of title 41, 
Code of Federal Regulations, the Committee shall enter into a 
written agreement with any such central nonprofit agency: Provided 
further, That such agreement shall contain such auditing, oversight, 
and reporting provisions as necessary to implement chapter 85 
of title 41, United States Code: Provided further, That such agree-
ment shall include the elements listed under the heading ‘‘Com-
mittee For Purchase From People Who Are Blind or Severely Dis-
abled—Written Agreement Elements’’ in the explanatory statement 
described in section 4 of Public Law 114–113 (in the matter pre-
ceding division A of that consolidated Act): Provided further, That 
any such central nonprofit agency may not charge a fee under 
section 51–3.5 of title 41, Code of Federal Regulations, prior to 
executing a written agreement with the Committee: Provided fur-
ther, That no less than $3,150,000 shall be available for the Office 
of Inspector General. 
CORPORATION FOR NATIONAL AND COMMUNITY SERVICE 
OPERATING EXPENSES 
For necessary expenses for the Corporation for National and 
Community Service (referred to in this title as ‘‘CNCS’’) to carry 
out the Domestic Volunteer Service Act of 1973 (referred to in 
this title as ‘‘1973 Act’’) and the National and Community Service 
Act of 1990 (referred to in this title as ‘‘1990 Act’’), $975,525,000, 
which shall be for the purposes and in the amounts specified in 
the ‘‘Final Bill’’ column for Corporation for National and Community 
Service in the ‘‘Departments of Labor, Health and Human Services, 
Education, and Related Agencies Appropriations Act, 2026’’ table 
in the explanatory statement described in section 4 (in the matter 
preceding division A of this consolidated Act), notwithstanding sec-
tions 198B(b)(3), 198S(g), 501(a)(4)(C), and 501(a)(4)(F) of the 1990 
Act: Provided, That of the amounts provided under this heading: 
(1) up to 1 percent of program grant funds may be used to defray 
the costs of conducting grant application reviews, including the 
use of outside peer reviewers and electronic management of the 
grants cycle; (2) the amounts made available for State Commission 
Support Grants shall be available to provide assistance to State 
commissions on national and community service, under section 
126(a) of the 1990 Act and notwithstanding section 501(a)(5)(B) 
of the 1990 Act; (3) of amounts made available for Innovation, 
Assistance, and Other Activities, $8,558,000 shall be available for
H. R. 7148—136 
expenses authorized under section 501(a)(4)(F) of the 1990 Act, 
which, notwithstanding the provisions of section 198P shall be 
awarded by CNCS on a competitive basis; and (4) of amounts 
made available for Innovation, Assistance, and Other Activities, 
$6,148,000 shall be available to carry out sections 198(k) and 198(i) 
of the 1990 Act: Provided further, That for the purposes of carrying 
out the 1990 Act, satisfying the requirements in section 122(c)(1)(D) 
may include a determination of need by the local community: Pro-
vided further, That CNCS shall award to each State their allotted 
amount under AmeriCorps State and National formula grants no 
later than April 1, 2026 and to each state their allotted amount 
under State Service Commission Support Grants and State Commis-
sion Investment Fund Grants no later than June 1, 2026: Provided 
further, That the Corporation shall support staffing levels necessary 
to fulfill its statutory responsibilities including carrying out pro-
grams, projects, and activities funded in this title of this Act in 
a timely manner. 
PAYMENT TO THE NATIONAL SERVICE TRUST 
(INCLUDING TRANSFER OF FUNDS) 
For payment to the National Service Trust established under 
subtitle D of title I of the 1990 Act, $180,000,000, to remain avail-
able until expended: Provided, That CNCS may transfer additional 
funds from the amount provided within ‘‘Operating Expenses’’ allo-
cated to grants under subtitle C of title I of the 1990 Act to 
the National Service Trust upon determination that such transfer 
is necessary to support the activities of national service participants 
and after notice is transmitted to the Committees on Appropriations 
of the House of Representatives and the Senate: Provided further, 
That amounts appropriated for or transferred to the National 
Service Trust may be invested under section 145(b) of the 1990 
Act without regard to the requirement to apportion funds under 
31 U.S.C. 1513(b). 
SALARIES AND EXPENSES 
For necessary expenses of administration as provided under 
section 501(a)(5) of the 1990 Act and under section 504(a) of the 
1973 Act, including payment of salaries, authorized travel, hire 
of passenger motor vehicles, the rental of conference rooms in 
the District of Columbia, the employment of experts and consultants 
authorized under 5 U.S.C. 3109, and not to exceed $2,500 for 
official reception and representation expenses, $89,686,000. 
OFFICE OF INSPECTOR GENERAL 
For necessary expenses of the Office of Inspector General in 
carrying out the Inspector General Act of 1978, $8,595,000, of 
which $1,000,000 shall be available until expended. 
ADMINISTRATIVE PROVISIONS 
SEC. 401. CNCS shall make any significant changes to program 
requirements, service delivery or policy only through public notice 
and comment rulemaking. For fiscal year 2026, during any grant
H. R. 7148—137 
selection process, an officer or employee of CNCS shall not know-
ingly disclose any covered grant selection information regarding 
such selection, directly or indirectly, to any person other than 
an officer or employee of CNCS that is authorized by CNCS to 
receive such information. 
SEC. 402. AmeriCorps programs receiving grants under the 
National Service Trust program shall meet an overall minimum 
share requirement of 24 percent for the first 3 years that they 
receive AmeriCorps funding, and thereafter shall meet the overall 
minimum share requirement as provided in section 2521.60 of title 
45, Code of Federal Regulations, without regard to the operating 
costs match requirement in section 121(e) or the member support 
Federal share limitations in section 140 of the 1990 Act, and subject 
to partial waiver consistent with section 2521.70 of title 45, Code 
of Federal Regulations. 
SEC. 403. Donations made to CNCS under section 196 of the 
1990 Act for the purposes of financing programs and operations 
under titles I and II of the 1973 Act or subtitle B, C, D, or 
E of title I of the 1990 Act shall be used to supplement and 
not supplant current programs and operations. 
SEC. 404. In addition to the requirements in section 146(a) 
of the 1990 Act, use of an educational award for the purpose 
described in section 148(a)(4) shall be limited to individuals who 
are veterans as defined under section 101 of the Act. 
SEC. 405. For the purpose of carrying out section 189D of 
the 1990 Act— 
(1) entities described in paragraph (a) of such section shall 
be considered ‘‘qualified entities’’ under section 3 of the National 
Child Protection Act of 1993 (‘‘NCPA’’); 
(2) individuals described in such section shall be considered 
‘‘volunteers’’ under section 3 of NCPA; and 
(3) State Commissions on National and Community Service 
established pursuant to section 178 of the 1990 Act, are author-
ized to receive criminal history record information, consistent 
with Public Law 92–544. 
SEC. 406. Notwithstanding sections 139(b), 146, and 147 of 
the 1990 Act, an individual who successfully completes a term 
of service of not less than 1,200 hours during a period of not 
more than one year may receive a national service education award 
having a value of 70 percent of the value of a national service 
education award determined under section 147(a) of the Act. 
SEC. 407. Section 148(f)(2)(A)(i) of the 1990 Act shall be applied 
by substituting ‘‘an approved national service position’’ for ‘‘a 
national service program that receives grants under subtitle C’’. 
SEC. 408. In any case where a participant of a position eligible 
for an educational award described in subtitle D of title I of the 
National and Community Service Act of 1990 (42 U.S.C. 12601 
et seq.) was required to exit the position early at the direction 
of the Corporation for National and Community Service and due 
to circumstances outside the control of the individual, such as 
a lapse in availability of Federal appropriations, or termination 
of their position, or the applicable program grant or agreement 
under the national service laws is released from completing the 
required term of service for such position, the Chief Executive 
Officer of the Corporation for National and Community Service 
may—
H. R. 7148—197 
days after the enactment of this Act: Provided further, That not 
to exceed 10 percent of any funding level specified in the table 
referred to in the second proviso under this heading in this Act 
may be transferred to any other funding level specified in such 
table: Provided further, That no transfer of such funding levels 
may increase or decrease any funding level in the table referred 
to in the second proviso under this heading in this Act by more 
than 10 percent: Provided further, That the preceding two provisos 
shall not apply to projects with full funding grant agreements 
under section 5309(d) of title 49, United States Code, included 
in the table referred to in the second proviso under this heading 
in this Act: Provided further, That for funds made available under 
this heading in division J of Public Law 117–58 the second through 
sixth provisos shall be treated as inapplicable for fiscal year 2026: 
Provided further, That for funds made available under this heading 
in division J of Public Law 117–58, $734,900,000 may be available 
for projects authorized under section 5309(d) of title 49, United 
States Code: Provided further, That for funds made available under 
this heading in division J of Public Law 117–58, $849,500,000 
may be available for projects authorized under section 5309(h) 
of title 49, United States Code: Provided further, That amounts 
repurposed under this heading in this Act shall continue to be 
treated as amounts specified in section 103(b) of division A of 
Public Law 118–5: Provided further, That the Secretary shall con-
tinue to administer the capital investment grants program in 
accordance with the procedural and substantive requirements of 
section 5309 of title 49, United States Code, and of section 3005(b) 
of the Fixing America’s Surface Transportation Act: Provided fur-
ther, That projects that receive a grant agreement under the expe-
dited project delivery for capital investment grants pilot program 
under section 3005(b) of the Fixing America’s Surface Transpor-
tation Act shall be deemed eligible for funding provided for projects 
under section 5309 of title 49, United States Code, without further 
evaluation or rating under such section: Provided further, That 
such funding shall not exceed the Federal share under section 
3005(b). 
GRANTS TO THE WASHINGTON METROPOLITAN AREA TRANSIT 
AUTHORITY 
For grants to the Washington Metropolitan Area Transit 
Authority as authorized under section 601 of division B of the 
Passenger Rail Investment and Improvement Act of 2008 (Public 
Law 110–432), $150,000,000, to remain available until expended: 
Provided, That the Secretary of Transportation shall approve grants 
for capital and preventive maintenance expenditures for the Wash-
ington Metropolitan Area Transit Authority only after receiving 
and reviewing a request for each specific project: Provided further, 
That the Secretary shall determine that the Washington Metropoli-
tan Area Transit Authority has placed the highest priority on 
those investments that will improve the safety of the system before 
approving such grants.
H. R. 7148—261 
(4) the item relating to ‘‘Supportive Living, Community 
Day Services, and Housing Site Project for Adults with Intellec-
tual and Developmental Disabilities’’ is deemed to be amended 
by striking project ‘‘Supportive Living, Community Day Serv-
ices, and Housing Site Project for Adults with Intellectual and 
Developmental Disabilities’’ and inserting ‘‘Community Day 
Services and Housing Expansion for Adults with Intellectual 
and Developmental Disabilities’’; 
(5) the item relating to ‘‘Public Library Addition’’ is deemed 
to be amended by striking project ‘‘Public Library Addition’’ 
and inserting ‘‘Public Library Renovations’’; 
(6) the item relating to ‘‘Renovation of Snelling Motel to 
Affordable Housing for Veterans’’ is deemed to be amended 
by striking project ‘‘Renovation of Snelling Motel to Affordable 
Housing for Veterans’’ and inserting ‘‘Acquisition for Affordable 
Housing for Veterans’’; 
(7) the item relating to ‘‘El Centro de la Raza-Pattison’s 
West Community Campus Property Acquisition’’ is deemed to 
be amended by striking project ‘‘El Centro de la Raza-Pattison’s 
West Community Campus Property Acquisition’’ and inserting 
‘‘Pattison’s West Community Campus’’; 
(8) the item relating to ‘‘Riverbrook Regional YMCA’’ is 
deemed to be amended by striking recipient ‘‘Riverbrook 
Regional Young Men’s Christian Association, Inc.’’ and inserting 
‘‘City of Norwalk’’; 
(9) the item relating to ‘‘The SE1 Rehab’’ is deemed to 
be amended by striking recipient ‘‘The Skid Row Housing Trust’’ 
and inserting ‘‘PATH Ventures’’ and striking project ‘‘The SE1 
Rehab’’ and inserting ‘‘Skid Row Permanent Supportive 
Housing Rehabilitation’’; 
(10) the item relating to ‘‘Community Aging & Retirement 
Services, Inc.’’ is deemed to be amended by striking recipient 
‘‘Community Aging & Retirement Services, Inc.’’ and inserting 
‘‘Pasco County,’’ and striking project ‘‘CARES One Stop Senior 
Center Acquisition and Construction’’ and inserting ‘‘Senior 
Center Acquisition and Construction’’; 
(11) the item relating to ‘‘Western Flyer Coast Guard Pier 
Repair and Classroom Design’’ is deemed to be amended by 
striking project ‘‘Western Flyer Coast Guard Pier Repair and 
Classroom Design’’ and inserting ‘‘Western Flyer Pier and 
Classroom Repair’’; 
(12) the item relating to ‘‘NYCHA ADA Accessibility and 
Security Lighting Project’’ is deemed to be amended by striking 
project ‘‘NYCHA ADA Accessibility and Security Lighting 
Project’’ and inserting ‘‘Installation of Exterior Lighting at 
Borinquen Plaza II’’; 
(13) the item relating to ‘‘Ausonia Apartments Moderniza-
tion’’ is deemed to be amended by striking recipient ‘‘Ausonia 
Apartments’’ and inserting ‘‘Boston Housing Authority’’; 
(14) the item relating to ‘‘Helping Up Mission Permanent 
Housing on East Baltimore Street’’ is deemed to be amended 
by striking ‘‘Helping Up Mission Permanent Housing on East 
Baltimore Street’’ and inserting ‘‘Greenspace Development in 
Baltimore’’; 
(15) the item relating to ‘‘The Choir School of Delaware’s 
New Building at 8th and West Street in Wilmington’s Historic 
Quaker Hill District’’ is deemed to be amended by striking
H. R. 7148—262 
‘‘at 8th and West Street in Wilmington’s Historic Quaker Hill 
District’’ and inserting ‘‘in Wilmington’’; 
(16) the item relating to ‘‘WTA 2011 Fixed Route Diesel 
to Electric Replacement Project, Bellingham’’ is deemed to be 
amended by striking ‘‘WTA 2011 Fixed Route Diesel to Electric 
Replacement Project, Bellingham’’ and inserting ‘‘Acquisition 
of Hybrid-Electric Buses’’; and 
(17) the item relating to ‘‘Media and Arts Collaborative 
Building Renovation’’ is deemed to be amended by striking 
‘‘Renovation’’. 
(c) In the table of projects entitled ‘‘Community Project Funding/ 
Congressionally Directed Spending’’ in the explanatory statement 
for division F of the Consolidated Appropriations Act, 2024 (Public 
Law 118–42) described in section 4 in the matter preceding division 
A of such Act— 
(1) the item relating to ‘‘Hardwoods Permanent Supportive 
Housing’’ is deemed to be amended by striking ‘‘Hardwoods’’; 
(2) the item relating to ‘‘Cle Elum—First Street Downtown 
Revitalization’’ is deemed to be amended by striking ‘‘First 
Street’’; 
(3) the item relating to ‘‘Center for Community Programs 
in Livermore Falls and Jay’’ is deemed to be amended by 
striking recipient ‘‘United Way of the Tri-Valley Area’’ and 
inserting ‘‘Town of Jay’’; 
(4) the item relating to ‘‘Pawtucket Library, Sayles Building 
Re-Pointing’’ is deemed to be amended by striking project ‘‘Paw-
tucket Library, Sayles Building Re-Pointing’’ and inserting 
‘‘Pawtucket Library, Sayles Building Renovation’’; 
(5) the item relating to ‘‘Germany Road Relocation Project’’ 
is deemed to be amended by striking project ‘‘Germany Road 
Relocation Project’’ and inserting ‘‘Sewer Improvements’’; 
(6) the item relating to ‘‘Community Center Expansion 
and Land Acquisition’’ is deemed to be amended by striking 
‘‘Expansion and Land Acquisition’’ and inserting ‘‘Planning and 
Design’’; 
(7) the item relating to ‘‘Laconia, NH Hill Street Pedestrian 
Bridge Replacement’’ is deemed to be amended by striking 
‘‘Hill Street’’ and inserting ‘‘Mill Street’’; 
(8) the item relating to ‘‘Sunnyside Community Reinvest-
ment as Cultura & Traditions: Tucson, AZ’’ is deemed to be 
amended by striking recipient ‘‘Sunnyside Foundation’’ and 
inserting ‘‘Sunnyside Unified School District’’; 
(9) the item relating to ‘‘Craighead Technology Park and 
Public Safety Center’’ is deemed to be amended by striking 
recipient ‘‘City Water and Light of Jonesboro’’ and inserting 
‘‘City of Jonesboro’’; 
(10) the item relating to ‘‘Capital Repairs of 4 Affordable 
Housing properties, City of Seattle, King County, WA’’ is 
deemed to be amended by striking ‘‘4’’ and inserting ‘‘3’’; 
(11) the item relating to ‘‘Middletown Plaza Elevator 
Replacement’’ is deemed to be amended by striking ‘‘Middletown 
Plaza Elevator Replacement’’ and inserting ‘‘Security Upgrades 
at NYCHA’s Soundview Houses’’; 
(12) the item relating to ‘‘Morris Affordable Housing Infra-
structure’’ is deemed to be amended by striking recipient 
‘‘Morris Affordable Housing Infrastructure’’ and inserting 
‘‘Morris Housing Authority’’;
H. R. 7148—460 
‘‘SEC. 126. Notwithstanding section 106, during the period 
ending on the last day of the first calendar quarter of 2026, section 
1930(a)(6)(B)(i) of title 28, United States Code, shall be applied 
as if ‘During the 5-year period’ were struck.’’. 
(b) APPLICATION OF AMENDMENTS MADE BY THE BANKRUPTCY 
ADMINISTRATION IMPROVEMENT ACT OF 2025.— 
(1) IN
GENERAL.—Section 6(b)(2)(A) of the Bankruptcy 
Administration Improvement Act of 2025 is amended by 
striking ‘‘on the’’ and inserting ‘‘on or after the’’. 
(2) EFFECTIVE DATE.—The amendment made by paragraph 
(1) shall take effect as though enacted immediately after the 
enactment of the Bankruptcy Administration Improvement Act 
of 2025. 
SEC. 5019. EXTENSION OF AFRICAN GROWTH AND OPPORTUNITY ACT. 
(a) EXTENSION
OF PREFERENTIAL TREATMENT
FOR CERTAIN 
COUNTRIES IN AFRICA UNDER AFRICAN GROWTH AND OPPORTUNITY 
ACT; RETROACTIVE APPLICATION.— 
(1) EXTENSION.— 
(A) TRADE ACT OF 1974.—Section 506B of the Trade 
Act of 1974 (19 U.S.C. 2466b) is amended by striking 
‘‘September 30, 2025’’ and inserting ‘‘December 31, 2026’’. 
(B) AFRICAN GROWTH AND OPPORTUNITY ACT.— 
(i) IN
GENERAL.—Section 112(g) of the African 
Growth and Opportunity Act (19 U.S.C. 3721(g)) is 
amended by striking ‘‘September 30, 2025’’ and 
inserting ‘‘December 31, 2026’’. 
(ii) REGIONAL APPAREL ARTICLE PROGRAM.—Section 
112(b)(3)(A) of the African Growth and Opportunity 
Act (19 U.S.C. 3721(b)(3)(A)) is amended— 
(I) in clause (i), by striking ‘‘21 succeeding’’ 
and inserting ‘‘23 succeeding’’; and 
(II) in clause (ii)(II), by striking ‘‘September 
30, 2025’’ and inserting ‘‘December 31, 2026’’. 
(iii) THIRD-COUNTRY
FABRIC
PROGRAM.—Section 
112(c)(1) of the African Growth and Opportunity Act 
(19 U.S.C. 3721(c)(1)) is amended— 
(I) in the paragraph heading, by striking ‘‘SEP-
TEMBER
30, 2025’’ and inserting ‘‘DECEMBER
31, 
2026’’; 
(II) in subparagraph (A), by striking ‘‘Sep-
tember 30, 2025’’ and inserting ‘‘December 31, 
2026’’; and 
(III) in subparagraph (B)(ii), by striking ‘‘Sep-
tember 30, 2025’’ and inserting ‘‘December 31, 
2026’’. 
(2) RETROACTIVE APPLICATION.— 
(A) IN GENERAL.—Notwithstanding section 514 of the 
Tariff Act of 1930 (19 U.S.C. 1514) or any other provision 
of law, and subject to subparagraph (B), any entry of a 
covered article to which duty-free treatment or other pref-
erential treatment under section 506A of the Trade Act 
of 1974 (19 U.S.C. 2466a) or section 112 of the African 
Grown and Opportunity Act (19 U.S.C. 3721) would have 
applied if the entry had been made on September 30, 
2025, that was made— 
(i) after September 30, 2025, and
H. R. 7148—475 
(A) in subparagraph (B)— 
(i) in the heading, by inserting ‘‘AND 2028’’ after 
‘‘2026’’; and 
(ii) in the matter preceding clause (i), by inserting 
‘‘and 2028’’ after ‘‘2026’’; 
(B) in subparagraph (C)— 
(i) in the heading, by striking ‘‘BEGINNING IN 2027’’ 
and inserting ‘‘2027 AND 2029 AND SUBSEQUENT YEARS’’; 
and 
(ii) in the matter preceding clause (i), by inserting 
‘‘and 2029’’ after ‘‘2027’’; and 
(C) in subparagraph (D), by striking ‘‘and 2026’’ and 
inserting ‘‘2026, and 2028’’; and 
(3) in paragraph (4)(B), by inserting ‘‘, or, with respect 
to 2028, 3.1 percent’’ after ‘‘1.88 percent’’. 
(b) CONFORMING AMENDMENTS.—Section 1848(q)(1)(C)(iii) of the 
Social Security Act (42 U.S.C. 1395w–4(q)(1)(C)(iii)) is amended— 
(1) in subclause (II), by inserting ‘‘and 2028’’ after ‘‘2026’’; 
and 
(2) in subclause (III), by inserting ‘‘and 2029’’ after ‘‘2027’’. 
SEC. 6205. EXTENSION OF FUNDING FOR QUALITY MEASURE ENDORSE-
MENT, INPUT, AND SELECTION. 
Section 1890(d)(2) of the Social Security Act (42 U.S.C. 
1395aaa(d)(2)) is amended— 
(1) in the first sentence— 
(A) by striking ‘‘and $13,300,000’’ and inserting 
‘‘$13,300,000’’; and 
(B) by inserting the following before the period at 
the end: ‘‘, and $15,100,000 for fiscal year 2027’’; and 
(2) in the third sentence, by striking ‘‘and 2026’’ and 
inserting ‘‘2026, and 2027’’. 
SEC. 6206. EXTENSION OF FUNDING OUTREACH AND ASSISTANCE FOR 
LOW-INCOME PROGRAMS. 
(a) STATE HEALTH INSURANCE ASSISTANCE PROGRAMS.—Sub-
section (a)(1)(B) of section 119 of the Medicare Improvements for 
Patients and Providers Act of 2008 (42 U.S.C. 1395b–3 note) is 
amended— 
(1) in clause (xiv), by striking ‘‘and’’ at the end; 
(2) in clause (xv), by striking the period at the end and 
inserting ‘‘; and’’; and 
(3) by inserting after clause (xv) the following new clause: 
‘‘(xvi) for the period beginning on January 31, 2026, 
and ending on December 31, 2027, $30,000,000.’’. 
(b) AREA AGENCIES ON AGING.—Subsection (b)(1)(B) of such 
section 119 is amended— 
(1) in clause (xiv), by striking ‘‘and’’ at the end; 
(2) in clause (xv), by striking the period at the end and 
inserting ‘‘; and’’; and 
(3) by inserting after clause (xv) the following new clause: 
‘‘(xvi) for the period beginning on January 31, 2026, 
and ending on December 31, 2027, $30,000,000.’’. 
(c) AGING
AND DISABILITY RESOURCE CENTERS.—Subsection 
(c)(1)(B) of such section 119 is amended— 
(1) in clause (xiv), by striking ‘‘and’’ at the end; 
(2) in clause (xv), by striking the period at the end and 
inserting ‘‘; and’’; and
H. R. 7148—476 
(3) by inserting after clause (xv) the following new clause: 
‘‘(xvi) for the period beginning on January 31, 2026, 
and ending on December 31, 2027, $10,000,000.’’. 
(d) COORDINATION OF EFFORTS TO INFORM OLDER AMERICANS 
ABOUT BENEFITS AVAILABLE UNDER FEDERAL
AND STATE PRO-
GRAMS.—Subsection (d)(2) of such section 119 is amended— 
(1) in clause (xiv), by striking ‘‘and’’ at the end; 
(2) in clause (xv), by striking the period at the end and 
inserting ‘‘; and’’; and 
(3) by inserting after clause (xv) the following new clause: 
‘‘(xvi) for the period beginning on January 31, 2026, 
and ending on December 31, 2027, $30,000,000.’’. 
SEC. 6207. EXTENSION OF FUNDING FOR MEDICARE HOSPICE SUR-
VEYS. 
Section 3(a)(2) of the IMPACT Act of 2014 (Public Law 113– 
185), as amended by section 6205 of division F of the Continuing 
Appropriations, Agriculture, Legislative Branch, Military Construc-
tion and Veterans Affairs, and Extensions Act, 2026 (Public Law 
119–37), is amended— 
(1) in subparagraph (B), by striking ‘‘and’’ at the end; 
(2) in subparagraph (C), by striking the period at the 
end and inserting ‘‘; and’’; and 
(3) by adding at the end the following new subparagraph: 
‘‘(D) $4,400,000 for the period beginning on January 
31, 2026, and ending on December 31, 2026, to remain 
available until expended.’’. 
SEC. 6208. EXTENSION OF THE WORK GEOGRAPHIC INDEX FLOOR. 
Section 1848(e)(1)(E) of the Social Security Act (42 U.S.C. 
1395w–4(e)(1)(E)) is amended by striking ‘‘January 31, 2026’’ and 
inserting ‘‘January 1, 2027’’. 
SEC. 6209. EXTENSION OF CERTAIN TELEHEALTH FLEXIBILITIES. 
(a) REMOVING GEOGRAPHIC REQUIREMENTS
AND EXPANDING 
ORIGINATING SITES FOR TELEHEALTH SERVICES.—Section 1834(m) 
of the Social Security Act (42 U.S.C. 1395m(m)) is amended— 
(1) in paragraph (2)(B)(iii), by striking ‘‘ending January 
30, 2026’’ and inserting ‘‘ending December 31, 2027’’; and 
(2) in paragraph (4)(C)(iii), by striking ‘‘ending on January 
30, 2026’’ and inserting ‘‘ending on December 31, 2027’’. 
(b) EXPANDING PRACTITIONERS ELIGIBLE
TO FURNISH TELE-
HEALTH SERVICES.—Section 1834(m)(4)(E) of the Social Security 
Act (42 U.S.C. 1395m(m)(4)(E)) is amended by striking ‘‘ending 
on January 30, 2026’’ and inserting ‘‘ending on December 31, 2027’’. 
(c) EXTENDING TELEHEALTH SERVICES FOR FEDERALLY QUALI-
FIED
HEALTH
CENTERS
AND
RURAL
HEALTH
CLINICS.—Section 
1834(m)(8)(A) of the Social Security Act (42 U.S.C. 1395m(m)(8)(A)) 
is amended by striking ‘‘ending on January 30, 2026’’ and inserting 
‘‘ending on December 31, 2027’’. 
(d) DELAYING THE IN-PERSON REQUIREMENTS UNDER MEDICARE 
FOR MENTAL HEALTH SERVICES FURNISHED THROUGH TELEHEALTH 
AND TELECOMMUNICATIONS TECHNOLOGY.— 
(1) DELAY IN REQUIREMENTS FOR MENTAL HEALTH SERVICES 
FURNISHED THROUGH TELEHEALTH.—Section 1834(m)(7)(B)(i) of 
the Social Security Act (42 U.S.C. 1395m(m)(7)(B)(i)) is 
amended, in the matter preceding subclause (I), by striking
H. R. 7148—501 
‘‘(ee) the average wholesale price for the 
drug, listed as price per day’s supply, price 
per dosage unit, and price per typical course 
of treatment (as applicable); 
‘‘(ff) the total out-of-pocket spending by 
plan enrollees on such drug after application 
of any benefits under the plan, including plan 
enrollee 
spending 
through 
copayments, 
coinsurance, and deductibles; 
‘‘(gg) total rebates paid by the manufac-
turer on the drug as reported under the 
Detailed DIR Report (or any successor report) 
submitted by such sponsor to the Centers for 
Medicare & Medicaid Services; 
‘‘(hh) all other direct or indirect remunera-
tion on the drug as reported under the 
Detailed DIR Report (or any successor report) 
submitted by such sponsor to the Centers for 
Medicare & Medicaid Services; 
‘‘(ii) the average pharmacy reimbursement 
amount paid by the plan for the drug in the 
aggregate and disaggregated by dispensing 
channel identified in item (cc); 
‘‘(jj) the average National Average Drug 
Acquisition Cost (NADAC); and 
‘‘(kk) total manufacturer-derived revenue, 
inclusive of bona fide service fees, attributable 
to the drug and retained by the pharmacy 
benefit manager and any affiliate of such phar-
macy benefit manager. 
‘‘(II) In the case of a pharmacy benefit man-
ager that has an affiliate that is a retail, mail 
order, or specialty pharmacy, with respect to drugs 
covered by such plan that were dispensed, the 
following information: 
‘‘(aa) The percentage of total prescriptions 
that were dispensed by pharmacies that are 
an affiliate of the pharmacy benefit manager 
for each drug. 
‘‘(bb) The interquartile range of the total 
combined costs paid by the plan and plan 
enrollees, per dosage unit, per course of treat-
ment, per 30-day supply, and per 90-day 
supply for each drug dispensed by pharmacies 
that are not an affiliate of the pharmacy ben-
efit manager and that are included in the 
pharmacy network of such plan. 
‘‘(cc) The interquartile range of the total 
combined costs paid by the plan and plan 
enrollees, per dosage unit, per course of treat-
ment, per 30-day supply, and per 90-day 
supply for each drug dispensed by pharmacies 
that are an affiliate of the pharmacy benefit 
manager and that are included in the phar-
macy network of such plan. 
‘‘(dd) The lowest total combined cost paid 
by the plan and plan enrollees, per dosage
H. R. 7148—502 
unit, per course of treatment, per 30-day 
supply, and per 90-day supply, for each drug 
that is available from any pharmacy included 
in the pharmacy network of such plan. 
‘‘(ee) The difference between the average 
acquisition cost of the affiliate, such as a phar-
macy or other entity that acquires prescription 
drugs, that initially acquires the drug and the 
amount reported under subclause (I)(jj) for 
each drug. 
‘‘(ff) A list inclusive of the brand name, 
generic or non-proprietary name, and National 
Drug Code of covered part D drugs subject 
to an agreement with a covered entity under 
section 340B of the Public Health Service Act 
for which the pharmacy benefit manager or 
an affiliate of the pharmacy benefit manager 
had a contract or other arrangement with such 
a covered entity in the service area of such 
plan. 
‘‘(III) Where a drug approved under section 
505(c) of the Federal Food, Drug, and Cosmetic 
Act (referred to in this subclause as the ‘listed 
drug’) is covered by the plan, the following informa-
tion: 
‘‘(aa) A list of currently marketed generic 
drugs approved under section 505(j) of the 
Federal Food, Drug, and Cosmetic Act pursu-
ant to an application that references such 
listed drug that are not covered by the plan, 
are covered on the same formulary tier or 
a formulary tier typically associated with 
higher cost-sharing than the listed drug, or 
are subject to utilization management that the 
listed drug is not subject to. 
‘‘(bb) The estimated average beneficiary 
cost-sharing under the plan for a 30-day 
supply of the listed drug. 
‘‘(cc) Where a generic drug listed under 
item (aa) is on a formulary tier typically asso-
ciated with higher cost-sharing than the listed 
drug, the estimated average cost-sharing that 
a beneficiary would have paid for a 30-day 
supply of each of the generic drugs described 
in item (aa), had the plan provided coverage 
for such drugs on the same formulary tier 
as the listed drug. 
‘‘(dd) A written justification for providing 
more favorable coverage of the listed drug than 
the generic drugs described in item (aa). 
‘‘(ee) The number of currently marketed 
generic drugs approved under section 505(j) 
of the Federal Food, Drug, and Cosmetic Act 
pursuant to an application that references 
such listed drug.
H. R. 7148—503 
‘‘(IV) Where a reference product (as defined 
in section 351(i) of the Public Health Service Act) 
is covered by the plan, the following information: 
‘‘(aa) A list of currently marketed bio-
similar biological products licensed under sec-
tion 351(k) of the Public Health Service Act 
pursuant to an application that refers to such 
reference product that are not covered by the 
plan, are covered on the same formulary tier 
or a formulary tier typically associated with 
higher 
cost-sharing 
than 
the 
reference 
product, or are subject to utilization manage-
ment that the reference product is not subject 
to. 
‘‘(bb) The estimated average beneficiary 
cost-sharing under the plan for a 30-day 
supply of the reference product. 
‘‘(cc) Where a biosimilar biological product 
listed under item (aa) is on a formulary tier 
typically associated with higher cost-sharing 
than the reference product, the estimated 
average cost-sharing that a beneficiary would 
have paid for a 30-day supply of each of the 
biosimilar biological products described in item 
(aa), had the plan provided coverage for such 
products on the same formulary tier as the 
reference product. 
‘‘(dd) A written justification for providing 
more favorable coverage of the reference 
product than the biosimilar biological products 
described in item (aa). 
‘‘(ee) The number of currently marketed 
biosimilar biological products licensed under 
section 351(k) of the Public Health Service 
Act, pursuant to an application that refers 
to such reference product. 
‘‘(V) Total gross spending on covered part D 
drugs by the plan, not net of rebates, fees, dis-
counts, or other direct or indirect remuneration. 
‘‘(VI) The total amount retained by the phar-
macy benefit manager or an affiliate of such phar-
macy benefit manager in revenue related to utiliza-
tion of covered part D drugs under that plan, 
inclusive of bona fide service fees. 
‘‘(VII) The total spending on covered part D 
drugs net of rebates, fees, discounts, or other direct 
and indirect remuneration by the plan. 
‘‘(VIII) An explanation of any benefit design 
parameters under such plan that encourage plan 
enrollees to fill prescriptions at pharmacies that 
are an affiliate of such pharmacy benefit manager, 
such as mail and specialty home delivery pro-
grams, and retail and mail auto-refill programs. 
‘‘(IX) The following information: 
‘‘(aa) A list of all brokers, consultants, 
advisors, and auditors that receive compensa-
tion from the pharmacy benefit manager or
H. R. 7148—504 
an affiliate of such pharmacy benefit manager 
for referrals, consulting, auditing, or other 
services offered to PDP sponsors related to 
pharmacy benefit management services. 
‘‘(bb) The amount of compensation pro-
vided by such pharmacy benefit manager or 
affiliate to each such broker, consultant, 
advisor, and auditor. 
‘‘(cc) The methodology for calculating the 
amount of compensation provided by such 
pharmacy benefit manager or affiliate, for each 
such broker, consultant, advisor, and auditor. 
‘‘(X) A list of all affiliates of the pharmacy 
benefit manager. 
‘‘(XI) A summary document submitted in a 
standardized template developed by the Secretary 
that includes such information described in sub-
clauses (I) through (X). 
‘‘(ii) WRITTEN
EXPLANATION
OF
CONTRACTS
OR 
AGREEMENTS WITH MANUFACTURERS.— 
‘‘(I) IN GENERAL.—The pharmacy benefit man-
ager shall, not later than 30 days after the finaliza-
tion of any contract or agreement between such 
pharmacy benefit manager or an affiliate of such 
pharmacy benefit manager and a manufacturer 
(or subsidiary, agent, or entity affiliated with such 
manufacturer) that makes rebates, discounts, pay-
ments, or other financial incentives related to one 
or more covered part D drugs or other prescription 
drugs, as applicable, of the manufacturer directly 
or indirectly contingent upon coverage, formulary 
placement, or utilization management conditions 
on any other covered part D drugs or other 
prescription drugs, as applicable, submit to the 
PDP sponsor a written explanation of such contract 
or agreement. 
‘‘(II) REQUIREMENTS.—A written explanation 
under subclause (I) shall— 
‘‘(aa) include the manufacturer subject to 
the contract or agreement, all covered part 
D drugs and other prescription drugs, as 
applicable, subject to the contract or agree-
ment and the manufacturers of such drugs, 
and a high-level description of the terms of 
such contract or agreement and how such 
terms apply to such drugs; and 
‘‘(bb) be certified by the Chief Executive 
Officer, Chief Financial Officer, or General 
Counsel of such pharmacy benefit manager, 
or affiliate of such pharmacy benefit manager, 
as applicable, or an individual delegated with 
the authority to sign on behalf of one of these 
officers, who reports directly to the officer. 
‘‘(III) DEFINITION
OF
OTHER
PRESCRIPTION 
DRUGS.—For purposes of this clause, the term 
‘other prescription drugs’ means prescription drugs
H. R. 7148—505 
covered as supplemental benefits under this part 
or prescription drugs paid outside of this part. 
‘‘(D) AUDIT RIGHTS.— 
‘‘(i) IN GENERAL.—Not less than once a year, at 
the request of the PDP sponsor, the pharmacy benefit 
manager shall allow for an audit of the pharmacy 
benefit manager to ensure compliance with all terms 
and conditions under the written agreement described 
in this paragraph and the accuracy of information 
reported under subparagraph (C). 
‘‘(ii) AUDITOR.—The PDP sponsor shall have the 
right to select an auditor. The pharmacy benefit man-
ager shall not impose any limitations on the selection 
of such auditor. 
‘‘(iii) PROVISION OF INFORMATION.—The pharmacy 
benefit manager shall make available to such auditor 
all records, data, contracts, and other information nec-
essary to confirm the accuracy of information reported 
under subparagraph (C), subject to reasonable restric-
tions on how such information must be reported to 
prevent redisclosure of such information. 
‘‘(iv) TIMING.—The pharmacy benefit manager 
must provide information under clause (iii) and other 
information, data, and records relevant to the audit 
to such auditor within 6 months of the initiation of 
the audit and respond to requests for additional 
information from such auditor within 30 days after 
the request for additional information. 
‘‘(v) INFORMATION
FROM
AFFILIATES.—The phar-
macy benefit manager shall be responsible for pro-
viding to such auditor information required to be 
reported under subparagraph (C) or under clause (iii) 
of this subparagraph that is owned or held by an 
affiliate of such pharmacy benefit manager. 
‘‘(2) ENFORCEMENT.— 
‘‘(A) IN GENERAL.—Each PDP sponsor shall— 
‘‘(i) disgorge to the Secretary any amounts dis-
gorged to the PDP sponsor by a pharmacy benefit 
manager under paragraph (1)(A)(v); 
‘‘(ii) require, in a written agreement with any phar-
macy benefit manager acting on behalf of such sponsor 
or affiliate of such pharmacy benefit manager, that 
such pharmacy benefit manager or affiliate reimburse 
the PDP sponsor for any civil money penalty imposed 
on the PDP sponsor as a result of the failure of the 
pharmacy benefit manager or affiliate to meet the 
requirements of paragraph (1) that are applicable to 
the pharmacy benefit manager or affiliate under the 
agreement; and 
‘‘(iii) require, in a written agreement with any 
such pharmacy benefit manager acting on behalf of 
such sponsor or affiliate of such pharmacy benefit man-
ager, that such pharmacy benefit manager or affiliate 
be subject to punitive remedies for breach of contract 
for failure to comply with the requirements applicable 
under paragraph (1).
H. R. 7148—516 
SEC. 6403. EXTENSION OF NATIONAL HEALTH SECURITY PROGRAMS. 
(a) Section 319(e)(8) of the Public Health Service Act (42 U.S.C. 
247d(e)(8)) is amended by striking ‘‘January 30, 2026’’ and inserting 
‘‘December 31, 2026’’. 
(b) Section 319L(e)(1)(D) of the Public Health Service Act (42 
U.S.C. 247d–7e(e)(1)(D)) is amended by striking ‘‘January 30, 2026’’ 
and inserting ‘‘December 31, 2026’’. 
(c) Section 319L–1(b) of the Public Health Service Act (42 
U.S.C. 247d–7f(b)) is amended by striking ‘‘January 30, 2026’’ and 
inserting ‘‘December 31, 2026’’. 
(d) Section 2811A(g) of the Public Health Service Act (42 U.S.C. 
300hh–10b(g)) is amended by striking ‘‘January 30, 2026’’ and 
inserting ‘‘December 31, 2026’’. 
(e) Section 2811B(g)(1) of the Public Health Service Act (42 
U.S.C. 300hh–10c(g)(1)) is amended by striking ‘‘January 30, 2026’’ 
and inserting ‘‘December 31, 2026’’. 
(f) Section 2811C(g)(1) of the Public Health Service Act (42 
U.S.C. 300hh–10d(g)(1)) is amended by striking ‘‘January 30, 2026’’ 
and inserting ‘‘December 31, 2026’’. 
(g) Section 2812(c)(4)(B) of the Public Health Service Act (42 
U.S.C. 300hh–11(c)(4)(B)) is amended by striking ‘‘January 30, 
2026’’ and inserting ‘‘December 31, 2026’’. 
SEC. 6404. NO SURPRISES ACT IMPLEMENTATION. 
Section 118(a) of division BB of the Consolidated Appropriations 
Act, 2021 (Public Law 116–260) is amended— 
(1) in paragraph (1), by striking ‘‘January 30, 2026’’ and 
inserting ‘‘December 31, 2026’’; and 
(2) in paragraph (2)— 
(A) 
by 
striking 
‘‘$14,000,000’’ 
and 
inserting 
‘‘$42,100,000’’; and 
(B) by striking ‘‘January 30, 2026’’ and inserting 
‘‘December 31, 2026’’. 
Subtitle B—World Trade Center Health 
Program 
SEC. 6411. 9/11 RESPONDER AND SURVIVOR HEALTH FUNDING 
CORRECTIONS. 
(a) IN GENERAL.—Section 3351(a)(2)(A) of the Public Health 
Service Act (42 U.S.C. 300mm–61(a)(2)(A)) is amended— 
(1) in clause (x), by striking ‘‘; and’’ and inserting a semi-
colon; 
(2) by redesignating clause (xi) as clause (xii); and 
(3) by inserting after clause (x), the following: 
‘‘(xi) for each of fiscal years 2026 through 2040— 
‘‘(I) 
the 
amount 
determined 
under 
this 
subparagraph for the previous fiscal year multi-
plied by 1.07; multiplied by 
‘‘(II) the ratio of— 
‘‘(aa) the total number of individuals 
enrolled in the WTC Program on July 1 of 
such previous fiscal year; to 
‘‘(bb) the total number of individuals so 
enrolled on July 1 of the fiscal year prior to 
such previous fiscal year; and’’.
H. R. 7148—517 
(b) REPORT TO CONGRESS.— 
(1) IN GENERAL.—Not later than 3 years after the date 
of enactment of this Act, the Secretary of Health and Human 
Services (referred to in this subsection as the ‘‘Secretary’’) shall 
conduct an assessment of anticipated budget authority and 
outlays of the World Trade Center Health Program (referred 
to in this subsection as the ‘‘Program’’) through the duration 
of the Program and submit a report summarizing such assess-
ment to— 
(A) the Speaker and minority leader of the House 
of Representatives; 
(B) the majority and minority leaders of the Senate; 
(C) the Committee on Health, Education, Labor, and 
Pensions and the Committee on the Budget of the Senate; 
and 
(D) the Committee on Energy and Commerce and the 
Committee on the Budget of the House of Representatives. 
(2) INCLUSIONS.—The report required under paragraph (1) 
shall include— 
(A) a projection of Program budgetary needs on a per- 
fiscal year basis through fiscal year 2090; 
(B) a review of Program modeling for each of fiscal 
years 2017 through the fiscal year prior to the fiscal year 
in which the report is issued to assess how anticipated 
budgetary needs compared to actual expenditures; 
(C) an assessment of the projected budget authority 
and expenditures of the Program through fiscal year 2090 
by comparing— 
(i) such projected authority and expenditures 
resulting from application of section 3351(a)(2)(A) of 
the Public Health Service Act (42 U.S.C. 300mm– 
61(a)(2)(A)), as amended by subsection (a); and 
(ii) such projected authority and expenditures that 
would result if such section were amended so that 
the formula under clause (xi) of such section, as 
amended by subsection (a), were to be extended 
through fiscal year 2090; and 
(D) any recommendations of the Secretary to make 
changes to the formula under such section 3351(a)(2)(A), 
as so amended, to fully offset anticipated Program expendi-
tures through fiscal year 2090. 
(c) TECHNICAL AMENDMENTS.—Title XXXIII of the Public Health 
Service Act (42 U.S.C. 300mm et seq.) is amended— 
(1) in section 3352(d) (42 U.S.C. 300mm–62(d)), by striking 
‘‘Any amounts’’ and inserting ‘‘Any unobligated amounts’’; 
(2) in section 3353(d) (42 U.S.C. 300mm–63(d)), by striking 
‘‘Any amounts’’ and inserting ‘‘Any unobligated amounts’’; and 
(3) in section 3354(d) (42 U.S.C. 300mm–64(d)), by striking 
‘‘Any amounts’’ and inserting ‘‘Any unobligated amounts’’. 
TITLE V—PUBLIC HEALTH PROGRAMS 
SEC. 6501. PREVENTING MATERNAL DEATHS. 
(a) MATERNAL
MORTALITY
REVIEW
COMMITTEES.—Section 
317K(d) of the Public Health Service Act (42 U.S.C. 247b–12(d)) 
is amended—
H. R. 7148—528 
(I) is the subject of a rare pediatric disease 
product application (as defined in section 529 of 
the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360ff)) for which a priority review voucher 
was awarded; and 
(II) was approved under section 505 of the 
Federal Food, Drug, and Cosmetic Act (42 U.S.C. 
355) or licensed under section 351 of the Public 
Health Service Act (42 U.S.C. 262). 
(ii) Whether, and to what extent, an unmet need 
related to the treatment or prevention of a rare pedi-
atric disease was met through the approval or licensure 
of such a drug or biological product. 
(iii) The size of the company to which a priority 
review voucher was awarded under section 529 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff) 
for such a drug or biological product. 
(iv) The value of such priority review voucher if 
transferred. 
(v) Identification of each drug for which a priority 
review voucher awarded under such section 529 was 
used. 
(vi) The size of the company using each priority 
review voucher awarded under such section 529. 
(vii) The length of the period of time between 
the date on which a priority review voucher was 
awarded under such section 529 and the date on which 
it was used. 
(viii) Whether, and to what extent, an unmet need 
related to the treatment or prevention of a rare pedi-
atric disease was met through the approval under sec-
tion 505 of the Federal Food, Drug, and Cosmetic Act 
(42 U.S.C. 355) or licensure under section 351 of the 
Public Health Service Act (42 U.S.C. 262) of a drug 
for which a priority review voucher was used. 
(ix) Whether, and to what extent, companies were 
motivated by the availability of priority review 
vouchers under section 529 of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 360ff) to attempt to 
develop a drug for a rare pediatric disease. 
(x) Whether, and to what extent, pediatric review 
vouchers awarded under such section were successful 
in stimulating development and expedited patient 
access to drug products for treatment or prevention 
of a rare pediatric disease that wouldn’t otherwise 
take place without the incentive provided by such 
vouchers. 
(xi) The impact of such priority review vouchers 
on the workload, review process, and public health 
prioritization efforts of the Food and Drug Administra-
tion. 
(xii) Any other incentives in Federal law that exist 
for companies developing drugs or biological products 
described in clause (i). 
(2) REPORT ON FINDINGS.—Not later than 5 years after 
the date of the enactment of this Act, the Comptroller General 
of the United States shall submit to the Committee on Energy
H. R. 7148—529 
and Commerce of the House of Representatives and the Com-
mittee on Health, Education, Labor, and Pensions of the Senate 
a report containing the findings of the study conducted under 
paragraph (1). 
SEC. 6605. LIMITATIONS ON EXCLUSIVE APPROVAL OR LICENSURE 
OF ORPHAN DRUGS. 
(a) IN GENERAL.—Section 527 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360cc) is amended— 
(1) in subsection (a), in the matter following paragraph 
(2), by striking ‘‘same disease or condition’’ and inserting ‘‘same 
approved use or indication within such rare disease or condi-
tion’’; 
(2) in subsection (b)— 
(A) in the matter preceding paragraph (1), by striking 
‘‘same rare disease or condition’’ and inserting ‘‘same 
approved use or indication for which such 7-year period 
applies to such already approved or licensed drug’’; and 
(B) in paragraph (1), by inserting ‘‘, relating to the 
approved use or indication,’’ after ‘‘the needs’’; 
(3) in subsection (c)(1), by striking ‘‘same rare disease or 
condition as the already approved drug’’ and inserting ‘‘same 
use or indication for which the already approved or licensed 
drug was approved or licensed’’; and 
(4) by adding at the end the following: 
‘‘(f) APPROVED USE OR INDICATION DEFINED.—In this section, 
the term ‘approved use or indication’ means the use or indication 
approved under section 505 of this Act or licensed under section 
351 of the Public Health Service Act for a drug designated under 
section 526 for a rare disease or condition.’’. 
(b) APPLICATION OF AMENDMENTS.—The amendments made by 
subsection (a) shall apply with respect to any drug designated 
under section 526 of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 360bb), regardless of the date on which the drug was 
so designated, and regardless of the date on which the drug was 
approved under section 505 of such Act (21 U.S.C. 355) or licensed 
under section 351 of the Public Health Service Act (42 U.S.C. 
262). 
Subtitle B—United States-Abraham 
Accords Cooperation and Security 
SEC. 6611. ESTABLISHMENT OF ABRAHAM ACCORDS OFFICE WITHIN 
FOOD AND DRUG ADMINISTRATION. 
(a) IN GENERAL.—Chapter X of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 391 et seq.) is amended by adding at 
the end the following: 
‘‘SEC. 1015. ABRAHAM ACCORDS OFFICE. 
‘‘(a) IN GENERAL.—The Secretary, acting through the Commis-
sioner of Food and Drugs, shall establish within the Food and 
Drug Administration an office, to be known as the Abraham Accords 
Office, to be headed by a director. 
‘‘(b) OFFICE.—Not later than 2 years after the date of enactment 
of this section, the Secretary shall—
H. R. 7148—535 
prescriptions at mail order, specialty, or retail 
pharmacies; 
‘‘(II) the percentage of total prescriptions dis-
pensed by such pharmacies to participants or bene-
ficiaries in such plan or coverage; and 
‘‘(III) a list of all drugs dispensed by such 
pharmacies to participants or beneficiaries enrolled 
in such plan or coverage, and, with respect to 
each drug dispensed— 
‘‘(aa) the amount charged, per dosage unit, 
per 30-day supply, or per 90-day supply (as 
applicable) to the plan or issuer, and to partici-
pants and beneficiaries; 
‘‘(bb) the median amount charged to such 
plan or issuer, and the interquartile range 
of the costs, per dosage unit, per 30-day 
supply, and per 90-day supply, including 
amounts paid by the participants and bene-
ficiaries, when the same drug is dispensed 
by other pharmacies that are not affiliated 
with or under common ownership with the 
entity and that are included in the pharmacy 
network of such plan or coverage; 
‘‘(cc) the lowest cost per dosage unit, per 
30-day supply and per 90-day supply, for each 
such drug, including amounts charged to the 
plan or coverage and to participants and bene-
ficiaries, that is available from any pharmacy 
included in the network of such plan or cov-
erage; and 
‘‘(dd) the net acquisition cost per dosage 
unit, per 30-day supply, and per 90-day 
supply, if such drug is subject to a maximum 
price discount; and 
‘‘(B) with respect to any group health plan, including 
group health insurance coverage offered in connection with 
such a plan, regardless of whether the plan or coverage 
is offered by a specified large employer or whether it is 
a specified large plan— 
‘‘(i) a summary document for the group health 
plan that includes such information described in 
clauses (i) through (iv) of subparagraph (A), as specified 
by the Secretary through guidance, program instruc-
tion, or otherwise (with no requirement of notice and 
comment rulemaking), that the Secretary determines 
useful to group health plans for purposes of selecting 
pharmacy benefit management services, such as an 
estimated net price to group health plan and partici-
pant or beneficiary, a cost per claim, the fee structure 
or reimbursement model, and estimated cost per 
participant or beneficiary; 
‘‘(ii) a summary document for plans and issuers 
to provide to participants and beneficiaries, which shall 
be made available to participants or beneficiaries upon 
request to their group health plan (including in the 
case of group health insurance coverage offered in 
connection with such a plan), that—
H. R. 7148—546 
supply, if such drug is subject to a maximum 
price discount; and 
‘‘(B) with respect to any group health plan, including 
group health insurance coverage offered in connection with 
such a plan, regardless of whether the plan or coverage 
is offered by a specified large employer or whether it is 
a specified large plan— 
‘‘(i) a summary document for the group health 
plan that includes such information described in 
clauses (i) through (iv) of subparagraph (A), as specified 
by the Secretary through guidance, program instruc-
tion, or otherwise (with no requirement of notice and 
comment rulemaking), that the Secretary determines 
useful to group health plans for purposes of selecting 
pharmacy benefit management services, such as an 
estimated net price to group health plan and partici-
pant or beneficiary, a cost per claim, the fee structure 
or reimbursement model, and estimated cost per 
participant or beneficiary; 
‘‘(ii) a summary document for plans and issuers 
to provide to participants and beneficiaries, which shall 
be made available to participants or beneficiaries upon 
request to their group health plan (including in the 
case of group health insurance coverage offered in 
connection with such a plan), that— 
‘‘(I) contains such information described in 
clauses (iii), (iv), (v), and (vi), as applicable, as 
specified by the Secretary through guidance, pro-
gram instruction, or otherwise (with no require-
ment of notice and comment rulemaking) that the 
Secretary determines useful to participants or 
beneficiaries in better understanding the plan or 
coverage or benefits under such plan or coverage; 
‘‘(II) contains only aggregate information; and 
‘‘(III) states that participants and beneficiaries 
may request specific, claims-level information 
required to be furnished under subsection (c) from 
the group health plan or health insurance issuer; 
and 
‘‘(iii) with respect to drugs covered by such plan 
or coverage during such reporting period— 
‘‘(I) the total net spending by the plan or cov-
erage for all such drugs; 
‘‘(II) the total amount received, or expected 
to be received, by the plan or issuer from any 
applicable entity in rebates, fees, alternative dis-
counts, or other remuneration; and 
‘‘(III) to the extent feasible, information on 
the total amount of remuneration for such drugs, 
including copayment assistance dollars paid, 
copayment cards applied, or other discounts pro-
vided by each drug manufacturer (or entity admin-
istering copayment assistance on behalf of such 
drug manufacturer) to participants and bene-
ficiaries; 
‘‘(iv) amounts paid directly or indirectly in rebates, 
fees, or any other type of compensation (as defined
H. R. 7148—566 
‘‘(I) the ingredient or ingredients that cause such drug not 
to be qualitatively or quantitatively the same as the listed drug; 
and 
‘‘(II) for any ingredient for which there is an identified quan-
titative deviation, the amount of such deviation. 
‘‘(iii) If the Secretary determines that such drug is qualitatively 
and quantitatively the same as the listed drug, the Secretary shall 
not change or rescind such determination after the submission 
of an abbreviated application for such drug under this subsection 
unless— 
‘‘(I) the formulation of the listed drug has been changed and 
the Secretary has determined that the prior listed drug formulation 
was withdrawn for reasons of safety or effectiveness; or 
‘‘(II) the Secretary makes a written determination that the 
prior determination must be changed because an error has been 
identified. 
‘‘(iv) If the Secretary makes a written determination described 
in clause (iii)(II), the Secretary shall provide notice and a copy 
of the written determination to the person making the request 
under clause (i). 
‘‘(v) The disclosures authorized under clauses (i) and (ii) are 
disclosures authorized by law, including for purposes of section 
1905 of title 18, United States Code. This subparagraph shall not 
otherwise be construed to authorize the disclosure of nonpublic 
qualitative or quantitative information about the ingredients in 
a listed drug, or to affect the status, if any, of such information 
as trade secret or confidential commercial information for purposes 
of section 301(j) of this Act, section 552 of title 5, United States 
Code, or section 1905 of title 18, United States Code.’’. 
(b) GUIDANCE.— 
(1) IN GENERAL.—Not later than one year after the date 
of enactment of this Act, the Secretary of Health and Human 
Services shall issue draft guidance, or update guidance, 
describing how the Secretary will determine whether a drug 
is qualitatively and quantitatively the same as the listed drug 
(as such terms are used in section 505(j)(3)(H) of the Federal 
Food, Drug, and Cosmetic Act, as added by subsection (a)), 
including with respect to assessing pH adjusters. 
(2) PROCESS.—In issuing guidance under this subsection, 
the Secretary of Health and Human Services shall— 
(A) publish draft guidance; 
(B) provide a period of at least 60 days for comment 
on the draft guidance; and 
(C) after considering any comments received and not 
later than one year after the close of the comment period 
on the draft guidance, publish final guidance.
H. R. 7148—567 
(c) APPLICABILITY.—Section 505(j)(3)(H) of the Federal Food, 
Drug, and Cosmetic Act, as added by subsection (a), applies begin-
ning on the date of enactment of this Act, irrespective of the 
date on which the guidance required by subsection (b) is finalized. 
Speaker of the House of Representatives. 
Vice President of the United States and
President of the Senate.